<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Pharmacology Corner &#187; Psychiatry</title>
	<atom:link href="http://pharmacologycorner.com/category/psychiatry/feed/" rel="self" type="application/rss+xml" />
	<link>http://pharmacologycorner.com</link>
	<description>Pharmacology CME for physicians, pharmacists and nurses.</description>
	<lastBuildDate>Mon, 12 Jul 2010 22:36:24 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.0</generator>
		<item>
		<title>An excellent animation on the mechanisms of drug addiction</title>
		<link>http://pharmacologycorner.com/mechanisms-drug-addiction-animation/</link>
		<comments>http://pharmacologycorner.com/mechanisms-drug-addiction-animation/#comments</comments>
		<pubDate>Sat, 10 Oct 2009 17:17:50 +0000</pubDate>
		<dc:creator>Flavio Guzmán, MD</dc:creator>
				<category><![CDATA[Pain drug therapy]]></category>
		<category><![CDATA[Pharmacology animations]]></category>
		<category><![CDATA[Psychiatry]]></category>
		<category><![CDATA[Videos]]></category>

		<guid isPermaLink="false">http://pharmacologycorner.com/?p=2482</guid>
		<description><![CDATA[The Genetic Science Learning Center at University of Utah developed an excellent animation depicting the mechanisms of addiction of most drugs of abuse. They use a cartoon-like approach to show biochemical changes in mouse brains.]]></description>
			<content:encoded><![CDATA[<p>The Genetic Science Learning Center at University of Utah developed an excellent animation depicting the mechanisms of addiction of most drugs of abuse. They use a cartoon-like approach to show molecular changes in mouse brains.<br />
<img class="aligncenter size-full wp-image-2483" title="drug_addiction_mechanisms" src="http://cdn.pharmacologycorner.com/wp-content/uploads/2009/09/drug_addiction_mechanisms.jpg" alt="drug_addiction_mechanisms" width="445" height="319" /></p>
<p style="text-align: center;"><strong><a href="http://learn.genetics.utah.edu/content/addiction/drugs/mouse.html" target="_blank">Watch animation</a></strong></p>
<p>They approach the following topics related to the neurobiology of drug addiction.</p>
<ul>
<li><a href="../methamphetamine-mechanism-addiction-brain-reward-system/">Methamphetamine</a> actions on dopamine vesicles.</li>
<li>LSD action on <a href="http://pharmacologycorner.com/serotonin-5ht-receptors-agonists-antagonist/">serotonin</a> receptors.</li>
<li>Heroin effects on opioid receptors .</li>
<li>How marijuana interacts with the cannabinoid system and its receptors.</li>
<li>Activation of the GABA-A <a href="../video-animation-mechanism-of-ionotropic-receptors-or-ligand-gated-ion-channels-lgics/">ionotropic receptor</a> by alcohol.</li>
<li>Cocaine action on dopamine reuptake.</li>
</ul>
<p>This blog has a related post that explains <a href="http://pharmacologycorner.com/video-molecular-mechanism-nicotine-addiction/">nicotine addiction mechanism</a> through a 3-D video animation.</p>
]]></content:encoded>
			<wfw:commentRss>http://pharmacologycorner.com/mechanisms-drug-addiction-animation/feed/</wfw:commentRss>
		<slash:comments>1</slash:comments>
		</item>
		<item>
		<title>PowerPoint presentations: antipsychotics (neuroleptics) pharmacology</title>
		<link>http://pharmacologycorner.com/powerpoints-reviewing-antipsychotics-neuroleptics-pharmacology/</link>
		<comments>http://pharmacologycorner.com/powerpoints-reviewing-antipsychotics-neuroleptics-pharmacology/#comments</comments>
		<pubDate>Tue, 21 Jul 2009 07:33:02 +0000</pubDate>
		<dc:creator>Flavio Guzmán, MD</dc:creator>
				<category><![CDATA[PowerPoint presentations]]></category>
		<category><![CDATA[Primary Care]]></category>
		<category><![CDATA[Psychiatry]]></category>
		<category><![CDATA[abilify]]></category>
		<category><![CDATA[Antipsychotics]]></category>
		<category><![CDATA[Butyrophenones]]></category>
		<category><![CDATA[mechanism of action]]></category>
		<category><![CDATA[Phenothiazines]]></category>

		<guid isPermaLink="false">http://pharmacologycorner.com/?p=1870</guid>
		<description><![CDATA[PPT files on antipsychotics (neuroleptics): it gathers lectures from different specialties (Family Medicine, Psychiatry) highlighting key pharmacological pearls.]]></description>
			<content:encoded><![CDATA[<p><img class="alignleft size-thumbnail wp-image-1886" title="schizophrenia" src="http://cdn.pharmacologycorner.com/wp-content/uploads/2009/07/schizophrenia-150x150.gif" alt="schizophrenia" width="150" height="150" />This set of <strong>PPT </strong>presentations is aimed to give an overview on <strong>neuroleptics </strong>(<strong>antipsychotics</strong>) through lectures developed by authors with slightly different backgrounds. Most of the PPT files have topics in common, such as: mechanism of action, classification of agents according to potency, differences between first and second generation, side effects profile, among others.</p>
<h3>Antipsychotics Review in Primary care. A PPT By Shomir Banerjee, M.D.</h3>
<p>Dr. Banerjee discusses the topic from a Family Medicine specialist point of view. Some other resources related to Family Medicine by the same author can be found at <a href="http://www.shomir.org">Shomir.org</a>.</p>
<p>Presentation outline:</p>
<ul>
<li>Differences between first and second generation antipsychotics.</li>
<li>How do typical and atypical Antipsychotics work? Mechanisms of action.</li>
<li>Classification by potency.</li>
<li>Acute extrapyramidal symptoms with high potency agents ( Akathisia, Dystonia, Parkinsonism).</li>
<li>Neuroleptic Malignant Syndrome.</li>
<li><a href="http://pharmacologycorner.com/fda-video-warning-on-metoclopramide-and-tardive-dyskinesia/">Tardive Dyskinesia.</a></li>
<li>Atypical vs Typical Antipsychotics.</li>
<li>Are atypicals “better?”</li>
<li>Monitoring</li>
<li>Analysis of agents: clozapine (Clozaril), olanzapine (Zyprexa), risperidone (Risperdal), quetiapine (Seroquel), ziprasidone (Geodon), aripiprazole (Abilify).</li>
</ul>
<div><object style="margin:0px" classid="clsid:d27cdb6e-ae6d-11cf-96b8-444553540000" width="425" height="355" codebase="http://download.macromedia.com/pub/shockwave/cabs/flash/swflash.cab#version=6,0,40,0"><param name="allowFullScreen" value="true" /><param name="allowScriptAccess" value="always" /><param name="src" value="http://static.slidesharecdn.com/swf/ssplayer2.swf?doc=antipsychoticsreviewprimarycare-090716160700-phpapp02&amp;stripped_title=review-primary-care" /><param name="allowfullscreen" value="true" /><embed style="margin:0px" type="application/x-shockwave-flash" width="425" height="355" src="http://static.slidesharecdn.com/swf/ssplayer2.swf?doc=antipsychoticsreviewprimarycare-090716160700-phpapp02&amp;stripped_title=review-primary-care" allowscriptaccess="always" allowfullscreen="true"></embed></object></div>
<p align="center"><a href="http://www.shomir.org/education/Antipsychotics%20Review%20Primary%20Care.ppt">Download PPT file</a></p>
<h3>Conventional Antipsychotics: Concise Review for  Non-Psychiatrists Treating Developmentally Disabled Population. A PPT by S. Christopher Shim, M.D.</h3>
<p>Dr. Shim is an American Psychiatric Association Distinguished Fellow who shares his practical approach on conventional antipsychotics with non-psychiatrists.</p>
<p>Presentation outline:</p>
<ul>
<li><a href="http://pharmacologycorner.com/equivalence-definition-in-pharmacology-three-kinds-of-equivalence/">Equivalence</a> between high potency agents: Haloperidol, fluphenazine, thiothixine, trifluoperazine, pimozide.</li>
<li>Equivalence between low potency agents: thioridazine, chlorpromazine, mesoridazine.</li>
<li>Benefits &amp; risks of high and low potency agents.</li>
<li>Safety and Tolerability –side effects profile-.</li>
<li>EPS (Extra Pyramidal Symptoms): features and treatment.</li>
<li>Cardiovascular effects: Malignant Arrhythmias (torsade de pointes), Sudden Cardiac Death</li>
<li>Cautions: Reduction or Discontinuation of Conventional Antipsychotic Medications</li>
</ul>
<div><object style="margin:0px" classid="clsid:d27cdb6e-ae6d-11cf-96b8-444553540000" width="425" height="355" codebase="http://download.macromedia.com/pub/shockwave/cabs/flash/swflash.cab#version=6,0,40,0"><param name="allowFullScreen" value="true" /><param name="allowScriptAccess" value="always" /><param name="src" value="http://static.slidesharecdn.com/swf/ssplayer2.swf?doc=conventionalantipsychotics2192007-090717080023-phpapp01&amp;stripped_title=conventional" /><param name="allowfullscreen" value="true" /><embed style="margin:0px" type="application/x-shockwave-flash" width="425" height="355" src="http://static.slidesharecdn.com/swf/ssplayer2.swf?doc=conventionalantipsychotics2192007-090717080023-phpapp01&amp;stripped_title=conventional" allowscriptaccess="always" allowfullscreen="true"></embed></object></div>
<p align="center"><a href="http://www.iidc.indiana.edu/Training/downloads/Conventional_Antipsychotics_2_19_2007.ppt">Download PPT file</a></p>
<h3>Treatment of Schizophrenia (and Related Psychotic Disorders). A PPT by Scott Stroup, MD, MPH.</h3>
<p>This presentation explores some of the most relevant clinical features of schizophrenia as well as other psychoses. It also reviews in chronological order of approval some of the most important neuroleptics (both first and second generation). As the presentations shown above, it highlights the most important side effects related to the use of antipsychotic medications. It also focuses on non-pharmacological therapies and other type of interventions .</p>
<div><object style="margin:0px" classid="clsid:d27cdb6e-ae6d-11cf-96b8-444553540000" width="425" height="355" codebase="http://download.macromedia.com/pub/shockwave/cabs/flash/swflash.cab#version=6,0,40,0"><param name="allowFullScreen" value="true" /><param name="allowScriptAccess" value="always" /><param name="src" value="http://static.slidesharecdn.com/swf/ssplayer2.swf?doc=schizophrenia1-090716160801-phpapp02&amp;stripped_title=schizophrenia1-1731610" /><param name="allowfullscreen" value="true" /><embed style="margin:0px" type="application/x-shockwave-flash" width="425" height="355" src="http://static.slidesharecdn.com/swf/ssplayer2.swf?doc=schizophrenia1-090716160801-phpapp02&amp;stripped_title=schizophrenia1-1731610" allowscriptaccess="always" allowfullscreen="true"></embed></object></div>
<p align="center"><a href="http://www.med.unc.edu/psyclerk/files/schizophrenia1.ppt">Download PPT file</a></p>
]]></content:encoded>
			<wfw:commentRss>http://pharmacologycorner.com/powerpoints-reviewing-antipsychotics-neuroleptics-pharmacology/feed/</wfw:commentRss>
		<slash:comments>6</slash:comments>
		</item>
		<item>
		<title>Methamphetamine mechanism of addiction in the brain reward system</title>
		<link>http://pharmacologycorner.com/methamphetamine-mechanism-addiction-brain-reward-system/</link>
		<comments>http://pharmacologycorner.com/methamphetamine-mechanism-addiction-brain-reward-system/#comments</comments>
		<pubDate>Sun, 05 Jul 2009 16:13:51 +0000</pubDate>
		<dc:creator>Flavio Guzmán, MD</dc:creator>
				<category><![CDATA[Neurology]]></category>
		<category><![CDATA[Psychiatry]]></category>
		<category><![CDATA[Videos]]></category>
		<category><![CDATA[crystal meth]]></category>
		<category><![CDATA[mechanism of action]]></category>
		<category><![CDATA[mesolimbic reward system]]></category>
		<category><![CDATA[methamphetamine]]></category>
		<category><![CDATA[nucleus accumbens]]></category>
		<category><![CDATA[positive reinforcement]]></category>
		<category><![CDATA[video animation]]></category>

		<guid isPermaLink="false">http://pharmacologycorner.com/?p=1817</guid>
		<description><![CDATA[A video by National Geographic discusses the mechanisms of addiction of Methamphetamine (also known as Meth and Tik).]]></description>
			<content:encoded><![CDATA[<p><a href="http://cdn.pharmacologycorner.com/wp-content/uploads/2009/07/methamphetamine_moa.jpg"><img title="methamphetamine_moa" style="border-top-width: 0px; display: inline; border-left-width: 0px; border-bottom-width: 0px; margin: 10px 10px 5px 0px; height: 81px; border-right-width: 0px" height="81" alt="methamphetamine_moa" src="http://cdn.pharmacologycorner.com/wp-content/uploads/2009/07/methamphetamine_moa_thumb.jpg" width="97" align="left" border="0" /></a> The following video by National Geographic discusses the mechanisms of addiction of Methamphetamine (also known as Meth and Tik).</p>
<p>It is oriented to a general audience. However, it’s useful to review the brain reward system and some important dopamine pathways.</p>
</p>
<div class="wlWriterEditableSmartContent" id="scid:5737277B-5D6D-4f48-ABFC-DD9C333F4C5D:d259f4e6-f6c0-4454-b120-0fdef974904f" style="padding-right: 0px; display: block; padding-left: 0px; float: none; padding-bottom: 0px; margin: 0px auto; width: 425px; padding-top: 0px">
<div><object width="425" height="355"><param name="movie" value="http://www.youtube.com/v/at3Sg6qvgTE&amp;hl=es&amp;fs=1&amp;&amp;hl=en"></param><embed src="http://www.youtube.com/v/at3Sg6qvgTE&amp;hl=es&amp;fs=1&amp;&amp;hl=en" type="application/x-shockwave-flash" width="425" height="355"></embed></object></div>
</div>
</p>
<p>You may also be interested in other posts such as: </p>
<ul>
<li><a href="http://pharmacologycorner.com/emea-reviewed-methylphenidate-ritalin-for-adhd-and-issued-recommendations-for-its-safer-use/">EMEA’s recommendations on Methylphenidate</a>.</li>
<li><a href="http://pharmacologycorner.com/recommendations-guidelines-methadone-chronic-pain/">Methadone for chronic pain</a>. </li>
</ul>
<h3>Further reading</h3>
<p>Addiction, Dopamine, and the Molecular Mechanisms of Memory. Neuron, Vol. 25, 515–532, March, 2000. <a href="http://humgen-www.med.nyu.edu/pharmacology/assets/Kramer/berke-hyman.pdf">Free Full Text – PDF -</a></p>
<p>Is there a common molecular pathway for addiction? EJ Nestler &#8211; Nature neuroscience, 2005.&#160; <a href="http://dept.wofford.edu/neuroscience/NeuroSeminar/pdfSpring2006/a7.pdf">Free Full Text – PDF -</a></p>
]]></content:encoded>
			<wfw:commentRss>http://pharmacologycorner.com/methamphetamine-mechanism-addiction-brain-reward-system/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Aripiprazole (Abilify) not approved for bipolar disorder</title>
		<link>http://pharmacologycorner.com/aripiprazole-abilify-not-approved-for-bipolar-disorder/</link>
		<comments>http://pharmacologycorner.com/aripiprazole-abilify-not-approved-for-bipolar-disorder/#comments</comments>
		<pubDate>Mon, 22 Jun 2009 03:13:11 +0000</pubDate>
		<dc:creator>Flavio Guzmán, MD</dc:creator>
				<category><![CDATA[Antidepressants]]></category>
		<category><![CDATA[Psychiatry]]></category>
		<category><![CDATA[abilify]]></category>
		<category><![CDATA[aripiprazole]]></category>
		<category><![CDATA[bipolar disorder]]></category>

		<guid isPermaLink="false">http://pharmacologycorner.com/aripiprazole-abilify-not-approved-for-bipolar-disorder/</guid>
		<description><![CDATA[According to a press release, the Scottish Medicines Consortium (SMC) did not accept aripiprazole for the treatment of manic episodes in bipolar I disorder and for the prevention of&#160; new manic episodes. According to the SMC, the manufacturer did not present a sufficiently robust economic analysis to gain acceptance. Psychiatrist Daniel Carlat from “The Carlat [...]]]></description>
			<content:encoded><![CDATA[<p>According to a <a href="http://www.scottishmedicines.org.uk/smc/6981.html">press release</a>, the Scottish Medicines Consortium (SMC) did not accept aripiprazole for the treatment of manic episodes in bipolar I disorder and for the prevention of&#160; new manic episodes. </p>
<p>According to the SMC, the manufacturer did not present a sufficiently robust economic analysis to gain acceptance.</p>
<p>Psychiatrist Daniel Carlat from “The Carlat Psychiatry&#160; Blog” <a href="http://carlatpsychiatry.blogspot.com/2009/05/abilify-and-great-akathisia-cover-up.html">refers to aripiprazole</a> as “ the antipsychotic most likely to cause akathisia”.</p>
<p>The video below is the US TV ad for Abilify. As you can see, there is an aggressive marketing campaign to promote aripiprazole as a medication in bipolar disorder, targeted both to prescribers and patients.</p>
<div class="wlWriterEditableSmartContent" id="scid:5737277B-5D6D-4f48-ABFC-DD9C333F4C5D:7ddaee03-cc69-46ab-b38a-363c3ae51f62" style="padding-right: 0px; display: inline; padding-left: 0px; float: none; padding-bottom: 0px; margin: 0px; padding-top: 0px">
<div><object width="425" height="355"><param name="movie" value="http://www.youtube.com/v/mmsjBdxDxcM&amp;hl=es&amp;fs=1&amp;rel=0&amp;hl=en"></param><embed src="http://www.youtube.com/v/mmsjBdxDxcM&amp;hl=es&amp;fs=1&amp;rel=0&amp;hl=en" type="application/x-shockwave-flash" width="425" height="355"></embed></object></div>
</div>
<p>As related information,&#160; SMC previously reviewed aripiprazole for <a href="http://pharmacologycorner.com/aripiprazole-im-abilify-for-agitation-control-in-patients-with-schizophrenia-smc-review/">agitation control in patients with schizophrenia</a> and accepted the IM formulation use only if oral therapy is not appropriate.</p>
]]></content:encoded>
			<wfw:commentRss>http://pharmacologycorner.com/aripiprazole-abilify-not-approved-for-bipolar-disorder/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Agomelatine (Valdoxan) for major depressive episodes</title>
		<link>http://pharmacologycorner.com/agomelatine-valdoxan-for-major-depressive-episodes/</link>
		<comments>http://pharmacologycorner.com/agomelatine-valdoxan-for-major-depressive-episodes/#comments</comments>
		<pubDate>Sun, 21 Jun 2009 18:10:05 +0000</pubDate>
		<dc:creator>Flavio Guzmán, MD</dc:creator>
				<category><![CDATA[Antidepressants]]></category>
		<category><![CDATA[Psychiatry]]></category>
		<category><![CDATA[5-HT2C]]></category>
		<category><![CDATA[depression]]></category>
		<category><![CDATA[melatonin agonist]]></category>
		<category><![CDATA[MT1 receptors]]></category>

		<guid isPermaLink="false">http://pharmacologycorner.com/?p=1728</guid>
		<description><![CDATA[Agomelatine (Valdoxan, Melitor, Thymanax) is a recently marketed new drug for the treatment of major depression with a novel mechanism of action. It can be included in the class of&#160; “other antidepressants”, or classified as a melatonergic drug. Mechanism of action Agomelatine acts as an agonist on melatonin MT1 and MT2 receptors. Additionally, it blocks [...]]]></description>
			<content:encoded><![CDATA[<p>Agomelatine (Valdoxan, Melitor, Thymanax) is a recently marketed new drug for the treatment of major depression with a novel mechanism of action. It can be included in the class of&#160; “other antidepressants”, or classified as a melatonergic drug. </p>
<h2>Mechanism of action</h2>
<p>Agomelatine acts as an agonist on melatonin MT1 and MT2 receptors. Additionally, it blocks serotonin 2C (5-HT2C) receptors.</p>
<p><a href="http://cdn.pharmacologycorner.com/wp-content/uploads/2009/07/agomelatine_mechanism_of_action.jpg"><img title="agomelatine_mechanism_of_action" style="border-right: 0px; border-top: 0px; display: block; float: none; margin-left: auto; border-left: 0px; margin-right: auto; border-bottom: 0px; height: 289px" height="289" alt="agomelatine_mechanism_of_action" src="http://cdn.pharmacologycorner.com/wp-content/uploads/2009/07/agomelatine_mechanism_of_action_thumb.jpg" width="514" border="0" /></a></p>
<h2>Efficacy and place in therapy</h2>
<p>On November 2008, EMEA issued a positive opinion for granting a Marketing Authorization to Valdoxan, after a resubmission by the applicant.&#160; Agomelatine was launched in the UK in June 2009 for the treatment of major depressive episodes in adults.</p>
<p>Few trials have compared agomelatine with&#160; &#8216;established&#8217; antidepressants like venlafaxine and sertraline. Most clinical trials compared agomelatine to placebo. As with most new drugs, time and experience from experts will tell which place it has on the therapeutic options for the treatment of depression. </p>
<p>The following document is a drug specific review for agomelatine by the London New Drugs Group.</p>
<h4>&#160;</h4>
<div><object codebase="http://download.macromedia.com/pub/shockwave/cabs/flash/swflash.cab#version=9,0,0,0" id="doc_175099565147701" name="doc_175099565147701" classid="clsid:d27cdb6e-ae6d-11cf-96b8-444553540000" align="middle"	height="600" width="550" ><param name="movie" value="http://d.scribd.com/ScribdViewer.swf?document_id=16637173&amp;access_key=key-3uf94jau7wng3e3f4ul&amp;page=1&amp;version=1&amp;viewMode=list"><param name="quality" value="high"><param name="play" value="true"><param name="loop" value="true"><param name="scale" value="showall"><param name="wmode" value="opaque"><param name="devicefont" value="false"><param name="bgcolor" value="#ffffff"><param name="menu" value="true"><param name="allowFullScreen" value="true"><param name="allowScriptAccess" value="always"><param name="salign" value=""><param name="mode" value="list"><embed src="http://d.scribd.com/ScribdViewer.swf?document_id=16637173&amp;access_key=key-3uf94jau7wng3e3f4ul&amp;page=1&amp;version=1&amp;viewMode=list" quality="high" pluginspage="http://www.macromedia.com/go/getflashplayer" play="true" loop="true" scale="showall" wmode="opaque" devicefont="false" bgcolor="#ffffff" name="doc_175099565147701_object" menu="true" allowfullscreen="true" allowscriptaccess="always" salign="" type="application/x-shockwave-flash" align="middle" mode="list" height="600" width="550"></embed></object></div>
<h4>&#160;</h4>
<h6 align="center">Download <a href="http://www.nelm.nhs.uk/en/Download/?file=MDs1MTA5NTE7L3VwbG9hZC9BZ29tZWxhdGluZSAyMDA5LnBkZg__.pdf">review (PDF file)</a></h6>
<h4>&#160;</h4>
<h4>&#160;</h4>
<h4>References and further reading</h4>
<p>Agomelatine for depression &#8211; horizon scanning review. Centre for Reviews and Dissemination. 2003.</p>
<p>J Pierre Olié, S Kasper.&#160; Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder (<a href="http://www.springerlink.com/content/11jgp8a5ttjap0j8/">abstract</a>). The International Journal of Neuropsychopharmacology, 2007. Cambridge Univ Press.</p>
<p>S.H. Kennedy , R. Emsley. Placebo-controlled trial of agomelatine in the treatment of major depressive disorder. (<a href="http://www.neurociencias-servier.com/pdf/Depresion/Agomelatine%20trial%20-%20Kennedy%20et%20al%20%20-%20Eur%20Neuropsy%20-%202006.pdf">PDF Free Full text</a>). European Neuropsychopharmacology, 2006. </p>
]]></content:encoded>
			<wfw:commentRss>http://pharmacologycorner.com/agomelatine-valdoxan-for-major-depressive-episodes/feed/</wfw:commentRss>
		<slash:comments>1</slash:comments>
		</item>
		<item>
		<title>Serotonin (5-HT): receptors, agonists and antagonists</title>
		<link>http://pharmacologycorner.com/serotonin-5ht-receptors-agonists-antagonist/</link>
		<comments>http://pharmacologycorner.com/serotonin-5ht-receptors-agonists-antagonist/#comments</comments>
		<pubDate>Tue, 17 Mar 2009 00:53:53 +0000</pubDate>
		<dc:creator>Flavio Guzmán, MD</dc:creator>
				<category><![CDATA[Antidepressants]]></category>
		<category><![CDATA[Antiemetics]]></category>
		<category><![CDATA[Gastrointestinal]]></category>
		<category><![CDATA[Neurology]]></category>
		<category><![CDATA[Psychiatry]]></category>
		<category><![CDATA[5-HT]]></category>
		<category><![CDATA[serotonin]]></category>
		<category><![CDATA[serotonin receptors]]></category>

		<guid isPermaLink="false">http://pharmacologycorner.com/?p=2345</guid>
		<description><![CDATA[Serotonin receptors characteristics, classification and drugs that influence serotonergic transmission. Pharmacology review.]]></description>
			<content:encoded><![CDATA[<p>Serotonin (<em>5</em>-hydroxytryptamine, <em>5</em>-<em>HT</em>) is a key mediator in the physiology of mood, vascular function and gastrointestinal motility. This explains the number of therapeutic agents that act targeting the serotonergic system such as: <a href="http://pharmacologycorner.com/serotonin-5-ht3-receptor-antagonists/">5-HT3 antagonists</a>, SSRIs and triptans.</p>
<p>This post will focus on the classification of <strong>serotonin receptors</strong>, as well as drug classes that act on serotonergic transmission. This includes 5-HT agonists, antagonists and medications that modulate 5-HT at the presynaptic level, all of them of very high clinical relevance. Overdose of a combitation of serotonergic agents can lead to <a href="http://pharmacologycorner.com/serotonin-syndrome-components-mnemonic/">serotonin syndrome.</a></p>
<p>Outline:</p>
<ul>
<li><a href="#serotonin receptors">Serotonin receptors</a></li>
<li><a href="#drugs on serotonergic">Drugs acting on serotonergic transmission</a>: <a href="#mao inhibitors">MAO inhibitors</a>, <a href="#SNRI">SNRIs</a>, <a href="#TCA">SSRIs</a></li>
<li><a href="#serotonin agonists">Serotonin agonists</a></li>
<li><a href="#serotonin antagonist">Serotonin antagonists</a></li>
</ul>
<h3><a name="serotonin receptors">Serotonin receptors classification</a></h3>
<p><img class="aligncenter size-full wp-image-2347" title="serotonin_5ht_receptors" src="http://cdn.pharmacologycorner.com/wp-content/uploads/2009/09/serotonin_5ht_receptors.jpg" alt="serotonin_5ht_receptors" width="433" height="475" /></p>
<p>Based on biochemical and pharmacological criteria, serotonin receptors are classified into seven main receptor subtypes, 5-HT1–7. Of major pharmacotherapeutic importance are those designated 5-HT1, 5-HT2, 5-HT4, and 5-HT7, all of which are <a href="http://pharmacologycorner.com/g-protein-coupled-receptors-3-d-video-and-text/">G-protein-coupled</a>, whereas the 5-HT3 subtype represents a <a href="http://pharmacologycorner.com/video-animation-mechanism-of-ionotropic-receptors-or-ligand-gated-ion-channels-lgics/">ligand-gated ion channel</a>.</p>
<p>5-HT1 receptors are subdivided into 5-HT1A, 5-HT1B, and 5-HT1D receptors; while 5-HT2 subtypes include 5-HT2A, 5-HT2B, and 5-HT2C.</p>
<h3><a name="drugs on serotonergic"> Drugs acting on serotonergic transmission</a></h3>
<p><img class="aligncenter size-full wp-image-2355" title="serotonin_presynaptic_modulators" src="http://cdn.pharmacologycorner.com/wp-content/uploads/2009/09/serotonin_presynaptic_modulators1.jpg" alt="serotonin_presynaptic_modulators" width="528" height="256" />The figure above depicts how serotonin neurotransmission may be modified at the presynaptic level by inhibiting degradation, storage or reuptake.</p>
<h4><a name="mao inhibitors">MAO inhibitors</a></h4>
<p>Monoamine oxidase is a key enzyme for serotonin, dopamine and norepinephrine inactivation. MAO inhibitors prevent inactivation of monoamines within a neuron, causing excess neurotransmitter to diffuse into the synaptic space. This class of agents is used in the treatment of depression (phenelzine, tranylcypromine, selegiline) and Parkinson&#8217;s disease (selegiline). Dietary restrictions (because of tyramine toxicity) limit their widespread use.</p>
<h4><a name="inhiitors of serotonin storage">Inhibitors of serotonin storage</a></h4>
<p>They interfere withe the ability of synaptic vesicles to store monoamines; displace serotonin, dopamine and norepinephrine from their storage in presynaptic nerve terminals. Agents that share this mechanism of action include amphetamine, methylphenidate and modafinil.</p>
<h4><a name="SNRI">Serotonin-norepinephrine reuptake inhibitors (SNRIs)</a></h4>
<p><a href="http://pharmacologycorner.com/differences-between-tricyclic-antidepressants-and-selective-serotonin-norepinephrine-reuptake-inhibitors-mechanism-of-action/">SNRIs mechanism</a> involves blockade of 5-HT and norepinephrine reuptake in a concentration-dependent manner. Agents in this class include venlafaxine and duloxetine, they may be effective for the treatment of depression in patients in whom SSRIs are ineffective.</p>
<h4><a name="SSRIs">Selective serotonin reuptake inhibitors (SSRIs)</a></h4>
<p>SSRIs block the reuptake of serotonin, leading to increased concentrations of the neurotransmitter in the synaptic cleft and to an enhanced postsynaptic neuronal activity.</p>
<h4><a name="TCA">Tricyclic-<strong>antidepressants (TCAs)</strong></a></h4>
<p><strong><a href="http://pharmacologycorner.com/differences-between-tricyclic-antidepressants-and-selective-serotonin-norepinephrine-reuptake-inhibitors-mechanism-of-action/">Tricyclic antidepressants </a></strong>act by inhibiting reuptake of 5-HT and norepinephrine from the synaptic cleft by respectively blocking 5-HT and norepinephrine reuptake transporters, thereby causing enhancement of postsynaptic response.</p>
<h3><strong><a name="serotonin agonists">Serotonin receptor agonists</a></strong></h3>
<p><strong><img class="aligncenter size-full wp-image-2361" title="serotonin_agonists" src="http://cdn.pharmacologycorner.com/wp-content/uploads/2009/09/serotonin_agonists.jpg" alt="serotonin_agonists" width="611" height="380" /></strong></p>
<p>Serotonin receptors agonists have wide clinical applications, from treatment of depression to abortive medications for migraine headache. According to the receptor they activate, they can be divided into:</p>
<p><strong><strong>5-HT1A agonists</strong></strong></p>
<p>Buspirone is a partial 5-HT1A agonist used clinically for the treatment of anxiety and depression.</p>
<p><strong><strong>5-HT1B and 5-HT1D agonists</strong></strong></p>
<p>The &#8220;triptans&#8221; are a drug class useful as abortive medication for the treatment of  acute migraine headaches. They are very effective medications that bind to 5-HT1B and 5-HT1D receptors in cranial vessels, which leads to vasoconstriction and decreased release of neuropeptides involved in &#8220;sterile inflammation&#8221;.</p>
<p><strong><strong>5-HT2C agonist</strong></strong></p>
<p>Trazodone was previously believed to be a 5-HT2C receptor antagonist. However,  recent publications report that trazodone would behave as a 5-HT2C agonist. This drug is used generally as somnorific.</p>
<p><strong><strong>5-HT4 agonists</strong></strong></p>
<p>Cisapride is a serotonin and cholinergic agonist used as a prokinetic drug, it was withdrawn from the U.S. market because of cardiovascular toxicity.</p>
<p><strong><strong>Non-selective agonists</strong></strong></p>
<p>Ergotamine activates a more than one subtype of 5-HT receptor, it binds to  5-HT1A, 5-HT1D, 5-HT1B, D2 and norepinephrine receptors. Its vasoconstrictor effect makes it a suitable treatment for migraine attacks.</p>
<p>LSD is a 5-HT1A, 5-HT2A, 5-HT2C, 5-HT5A, 5-HT5, 5-HT6 agonist that has psychedelic properties.</p>
<h3><strong><a name="serotonin antagonist">Serotonin receptor antagonists</a></strong></h3>
<p><strong><img class="aligncenter size-full wp-image-2369" title="serotonin_antagonists" src="http://cdn.pharmacologycorner.com/wp-content/uploads/2009/09/serotonin_antagonists.jpg" alt="serotonin_antagonists" width="538" height="222" /></strong></p>
<p><strong><strong>5-HT2 antagonists</strong></strong></p>
<p>Ketanserin is a 5-HT2A/2C antagonist used for the treatment of hypertension. In addition to its serotonin antagonism, it has affinity for alpha-1 receptors, which may contribute to its antihypertensive effect.</p>
<p>Clozapine is an atypical <a href="http://pharmacologycorner.com/powerpoints-reviewing-antipsychotics-neuroleptics-pharmacology/">antipsychotic </a>drug that acts as 5-HT2A/2C receptor antagonist with high affinity for dopamine receptors.   It represents a class of atypical antipsychotic drugs, one key advantage of this group is its reduced incidence of  extrapyramidal side effects compared to the classical antipsychotics, and possibly  a greater efficacy for reducing negative symptoms of schizophrenia.</p>
<p><a href="http://pharmacologycorner.com/agomelatine-valdoxan-for-major-depressive-episodes/">Agomelatine</a> is a new antidepressant with agonist action at the melatonin receptor and antagonism at the 5-HT2C receptor.</p>
<p><strong><strong><a href="http://pharmacologycorner.com/serotonin-5-ht3-receptor-antagonists/">5-HT3 antagonists</a></strong></strong></p>
<p>This class includes drugs such as <a href="http://pharmacologycorner.com/serotonin-5-ht3-receptor-antagonists/">ondansetron</a>, palonosetron and others. These agents are particularly useful in the treatment of chemotherapy induced nausea and vomiting (CINV).</p>
<p><em>The figures used in this post were created using the <a href="http://bubbl.us/">Bubble.us application for online mind mapping</a>.</em></p>
<h4><strong>References and further reading</strong></h4>
<p><em>Golan, David E (editor). “Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy”, 2nd edition. LWW: 2008.</em></p>
<p><em>Harvey, R; Champe, P (series editors). “Lippincott illustrated reviews: Pharmacology”, 4th edition. LWW: 2009.</em></p>
<p><em>Brunton, L.B., Lazo, J.S., &amp; Parker, K.L. (Eds.).  <em>&#8220;Goodman &amp; Gilman&#8217;s the pharmacological basis of therapeutics</em>&#8220;,  11th edition. New York: McGraw-Hill:2005.</em></p>
]]></content:encoded>
			<wfw:commentRss>http://pharmacologycorner.com/serotonin-5ht-receptors-agonists-antagonist/feed/</wfw:commentRss>
		<slash:comments>7</slash:comments>
		</item>
		<item>
		<title>Analysis of antidepressants effectiveness in adolescents: InfoPOEMs podcast</title>
		<link>http://pharmacologycorner.com/analysis-of-antidepressants-effectiveness-in-adolescents-infopoems-podcast/</link>
		<comments>http://pharmacologycorner.com/analysis-of-antidepressants-effectiveness-in-adolescents-infopoems-podcast/#comments</comments>
		<pubDate>Mon, 16 Mar 2009 14:46:35 +0000</pubDate>
		<dc:creator>Flavio Guzmán, MD</dc:creator>
				<category><![CDATA[Antidepressants]]></category>
		<category><![CDATA[Podcasts]]></category>
		<category><![CDATA[Psychiatry]]></category>
		<category><![CDATA[evidence based medicine]]></category>
		<category><![CDATA[SNRIs]]></category>
		<category><![CDATA[SSRIs]]></category>

		<guid isPermaLink="false">http://pharmacologycorner.com/analysis-of-antidepressants-effectiveness-in-adolescents-infopoems-podcast/</guid>
		<description><![CDATA[Essential Evidence Plus, formerly InfoPOEMs is a service by John Wiley and Sons that aims to give physicians succinct medical evidence that will impact in their medical practice. In this podcast Dr. Ebell and Dr. Wilkes (National Public Radio) discuss the POEM titled: “Antidepressants only modestly effective for adolescent depression” Listen to the podcast on [...]]]></description>
			<content:encoded><![CDATA[<p><a href="http://www.essentialevidenceplus.com/"><img height="126" src="http://cdn.pharmacologycorner.com/wp-content/uploads/2009/02/podcast-thumb.jpg" width="162" align="right" />Essential Evidence Plus</a>, formerly InfoPOEMs is a service by John Wiley and Sons that aims to give physicians succinct medical evidence that will impact in their medical practice.</p>
<p>In this podcast Dr. Ebell and Dr. Wilkes (National Public Radio) discuss the POEM titled:</p>
<p>“Antidepressants only modestly effective for adolescent depression”</p>
<p>Listen to the podcast on <a title="http://www.essentialevidenceplus.com/netcasts/ipweekly_ep070.mp3" href="http://www.essentialevidenceplus.com/netcasts/ipweekly_ep070.mp3">antidepressants for adolescent depression</a>.</p>
]]></content:encoded>
			<wfw:commentRss>http://pharmacologycorner.com/analysis-of-antidepressants-effectiveness-in-adolescents-infopoems-podcast/feed/</wfw:commentRss>
		<slash:comments>1</slash:comments>
<enclosure url="http://www.essentialevidenceplus.com/netcasts/ipweekly_ep070.mp3" length="3235296" type="audio/mpeg" />
		</item>
		<item>
		<title>NPS: Desvenlafaxine (Pristiq) not superior to venlafaxine for major depressive disorder</title>
		<link>http://pharmacologycorner.com/nps-desvenlafaxine-pristiq-not-superior-to-venlafaxine-for-major-depressive-disorder/</link>
		<comments>http://pharmacologycorner.com/nps-desvenlafaxine-pristiq-not-superior-to-venlafaxine-for-major-depressive-disorder/#comments</comments>
		<pubDate>Wed, 11 Mar 2009 01:01:15 +0000</pubDate>
		<dc:creator>Flavio Guzmán, MD</dc:creator>
				<category><![CDATA[Antidepressants]]></category>
		<category><![CDATA[Psychiatry]]></category>
		<category><![CDATA[desvenlafaxine]]></category>
		<category><![CDATA[pristiq]]></category>
		<category><![CDATA[SNRIs]]></category>
		<category><![CDATA[venlafaxine]]></category>

		<guid isPermaLink="false">http://pharmacologycorner.com/nps-desvenlafaxine-pristiq-not-superior-to-venlafaxine-for-major-depressive-disorder/</guid>
		<description><![CDATA[The National Prescribing Service Limited (Australia) made an independent evaluation on the role of desvenlafaxine (Pristiq) for the treatment of major depressive disorder. Summary: Desvenlafaxine is the active metabolite of venlafaxine. There is no evidence that desvenlafaxine is more effective, safer or better tolerated than venlafaxine or other antidepressants. Doses above 50 mg/day are unlikely [...]]]></description>
			<content:encoded><![CDATA[<p>The National Prescribing Service Limited (Australia) made an independent evaluation on the <a href="http://nps.org.au/health_professionals/publications/nps_radar/issues/current/march_2009/desvenlafaxine" rel="nofollow">role of desvenlafaxine (Pristiq) for the treatment of major depressive disorder</a>. </p>
<p>Summary:</p>
<ul>
<ul>
<li>Desvenlafaxine is the active metabolite of venlafaxine. </li>
<li>There is no evidence that desvenlafaxine is more effective, safer or better tolerated than venlafaxine or other antidepressants. </li>
<li>Doses above 50 mg/day are unlikely to provide further clinical benefit and are associated with a higher incidence of adverse effects. </li>
<li>Common adverse effects include nausea, headache, dizziness, dry mouth and diarrhoea. </li>
<li>Desvenlafaxine should not be used in children and adolescents. </li>
<li>Reduce the dose slowly to avoid discontinuation symptoms.</li>
</ul>
</ul>
<p>In an article published in Annals of Pharmacotherapy.&#160; <a href="http://www.theannals.com/cgi/content/abstract/aph.1K563v1">Desvenlafaxine: Another &quot;Me Too&quot; Drug?,</a> the authors conclude:</p>
<blockquote><p>“With the overall similarity between these<sup> </sup>2 drugs and the potential lack of cost savings, the need for<sup> </sup>desvenlafaxine and its ultimate utility in treating major<sup> </sup>depressive disorder appears to be insignificant.”</p>
</blockquote>
]]></content:encoded>
			<wfw:commentRss>http://pharmacologycorner.com/nps-desvenlafaxine-pristiq-not-superior-to-venlafaxine-for-major-depressive-disorder/feed/</wfw:commentRss>
		<slash:comments>1</slash:comments>
		</item>
		<item>
		<title>Atomoxetine (Strattera) for ADHD: risk of psychotic or manic symptoms</title>
		<link>http://pharmacologycorner.com/atomoxetine-strattera-for-adhd-risk-of-psychotic-or-manic-symptoms/</link>
		<comments>http://pharmacologycorner.com/atomoxetine-strattera-for-adhd-risk-of-psychotic-or-manic-symptoms/#comments</comments>
		<pubDate>Wed, 04 Mar 2009 21:33:37 +0000</pubDate>
		<dc:creator>Flavio Guzmán, MD</dc:creator>
				<category><![CDATA[Drug safety]]></category>
		<category><![CDATA[Neurology]]></category>
		<category><![CDATA[Psychiatry]]></category>
		<category><![CDATA[ADHD]]></category>
		<category><![CDATA[atomoxetine]]></category>
		<category><![CDATA[MHRA]]></category>
		<category><![CDATA[psychotic symptoms]]></category>
		<category><![CDATA[SNRIs]]></category>
		<category><![CDATA[strattera]]></category>

		<guid isPermaLink="false">http://pharmacologycorner.com/atomoxetine-strattera-for-adhd-risk-of-psychotic-or-manic-symptoms/</guid>
		<description><![CDATA[The Medicines and Healthcare products Regulatory Agency (MHRA) has published Drug Safety Update for March 2009. One of the drugs reviewed is atomoxetin (Strattera), a norepinephrine reuptake inhibitor used for the treatment of ADHD. These are the recommendations: Advice for healthcare professionals: • At normal doses, atomoxetine can be associated with treatment-emergent psychotic or manic [...]]]></description>
			<content:encoded><![CDATA[<p>The <a href="http://www.mhra.gov.uk/">Medicines and Healthcare products Regulatory Agency</a> (MHRA) has published <a href="http://www.mhra.gov.uk/Publications/Safetyguidance/DrugSafetyUpdate/CON041211">Drug Safety Update</a> for March 2009. One of the drugs reviewed is atomoxetin (Strattera), a  norepinephrine reuptake inhibitor used for the treatment of ADHD. These are the recommendations:</p>
<blockquote><p>Advice for healthcare professionals:<br />
• At normal doses, atomoxetine can be associated with treatment-emergent psychotic or manic symptoms (eg, hallucinations, delusional thinking, mania, or agitation) in children and adolescents without a history of psychotic illness or mania.<br />
• If such symptoms occur , consideration should be given to a possible causal role of atomoxetine and discontinuation of treatment.<br />
• It remains possible that atomoxetine might exacerbate pre-existing psychotic or manic symptoms.</p></blockquote>
<p>The Midlands Therapeutics Review and Advisory Committee stated in a May 2006 <a href="http://www.keele.ac.uk/schools/pharm/images/fohpdf.gif">verdict and summary of atomoxetine:</a></p>
<blockquote><p>“Initiation of atomoxetine treatment and stabilisation of the dose should be the responsibility of a specialist. It is then appropiate to prescribe atomoxetine in primary care with the guidance of an ESCA”.</p></blockquote>
<p>Recently (January 2009), the FDA reminded about the <a href="http://pharmacologycorner.com/atomoxetine-strattera-and-the-risk-of-serious-hepatic-damage-fda-recommendations/">risk of serious hepatic damage with atomoxetine.</a></p>
]]></content:encoded>
			<wfw:commentRss>http://pharmacologycorner.com/atomoxetine-strattera-for-adhd-risk-of-psychotic-or-manic-symptoms/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>MCQs for USMLE review on psychopharmacology: antipsychotics, benzodiazepines, antidepressants and lithium</title>
		<link>http://pharmacologycorner.com/mcqs-for-usmle-review-on-psychopharmacology-antipsychotics-benzodiazepines-antidepressants-and-lithium/</link>
		<comments>http://pharmacologycorner.com/mcqs-for-usmle-review-on-psychopharmacology-antipsychotics-benzodiazepines-antidepressants-and-lithium/#comments</comments>
		<pubDate>Sun, 01 Mar 2009 21:21:00 +0000</pubDate>
		<dc:creator>Flavio Guzmán, MD</dc:creator>
				<category><![CDATA[Antidepressants]]></category>
		<category><![CDATA[Antipsychotics]]></category>
		<category><![CDATA[Benzodiazepines and Z-drugs]]></category>
		<category><![CDATA[MCQs and quizzes for USMLE]]></category>
		<category><![CDATA[Psychiatry]]></category>
		<category><![CDATA[benzos]]></category>
		<category><![CDATA[lithium]]></category>
		<category><![CDATA[mao inhibitors]]></category>
		<category><![CDATA[neuroleptics]]></category>
		<category><![CDATA[side effects]]></category>
		<category><![CDATA[SSRIs]]></category>
		<category><![CDATA[triciclic antidepressants]]></category>

		<guid isPermaLink="false">http://pharmacologycorner.com/mcqs-for-usmle-review-on-psychopharmacology-antipsychotics-benzodiazepines-antidepressants-and-lithium/</guid>
		<description><![CDATA[These pharmacology MCQs from the UMKC School of Medicine have a different degree of difficulty, but are useful to review pharmacology of psychotropics. Psychotropics Item Number: 11667 correct answer: 4 category: Psychotropics 1. The symptoms of tardive dyskinesia will acutely improve with: 1. administration of diphenhydramine 2. administration of amantadine 3. administration of bromocriptine 4. [...]]]></description>
			<content:encoded><![CDATA[<p>These <a href="http://pharmacologycorner.com/usmle-mcqs-pharmacology-practice-questions/">pharmacology MCQs</a> from the <a href="http://www.med.umkc.edu/pharm/">UMKC School of Medicine</a> have a different degree of difficulty, but are useful to review pharmacology of psychotropics.</p>
<p>Psychotropics<br />
Item Number: 11667 correct answer: 4 category: Psychotropics<br />
1. The symptoms of tardive dyskinesia will acutely improve with:<br />
1. administration of diphenhydramine<br />
2. administration of amantadine<br />
3. administration of bromocriptine<br />
4. increase of neuroleptic dose<br />
5. All of the above</p>
<p>Item Number: 8777 correct answer: 5 category: Psychotropics<br />
2. Psychopharmacology includes the judicious of all the following EXCEPT:<br />
1. haloperidol<br />
2. lithium carbonate<br />
3. imipramine<br />
4. chlordiazepoxide<br />
5. selegiline</p>
<p><span id="more-1261"></span></p>
<p>Item Number: 11641 correct answer: 2 category: Psychotropics<br />
3. Major tranquilizers of the phenothiazine group produce all of the following<br />
EXCEPT:<br />
1. autonomic effects<br />
2. anesthesia<br />
3. extrapyramidal effects<br />
4. control of psychotic behavior<br />
5. prevention of vomiting</p>
<p>Item Number: 11652 correct answer: 4 category: Psychotropics<br />
4. Neuroleptic malignant syndrome is characterized by all of the following<br />
EXCEPT:<br />
1. hyperpyrexia<br />
2. increase in serum creatine phosphokinase<br />
3. catatonia<br />
4. akathisia<br />
5. All of the above</p>
<p>Item Number: 10533 correct answer: 5 category: Psychotropics<br />
5. Pigment deposits in the anterior lens capsule and posterior surface of the<br />
cornea can be seen by slit-lamp examination in one third to one half of some<br />
groups receiving certain phenothiazine tranquilizers. Phenothiazine<br />
tranquilizers which have caused this state include:<br />
1. chlorpromazine<br />
2. promazine<br />
3. thioridazine<br />
4. All of the above<br />
5. 1,3</p>
<p>Item Number: 11754 correct answer: 4 category: Psychotropics<br />
6. Pharmacologic effects of thioridazine include all of the following EXCEPT:<br />
1. control of psychotic behavior<br />
2. orthostatic hypotension<br />
3. antiemesis<br />
4. hypoprolactinemia<br />
5. All of the above</p>
<p>Item Number: 10699 correct answer: 2 category: Psychotropics<br />
7. A substance which decreases or inhibits the metabolism of <a href="http://pharmacologycorner.com/animation-benzodiazepines-diazepam-lorazepam-alprazolam/">benzodiazepines</a><br />
metabolized to active metabolites in the liver is:<br />
1. ranitidine<br />
2. cimetidine<br />
3. rifampin<br />
4. carbamazepine<br />
5. phenytoin</p>
<p>Item Number: 10484 correct answer: 5 category: Psychotropics<br />
8. Systems on which <a href="http://pharmacologycorner.com/powerpoints-reviewing-antipsychotics-neuroleptics-pharmacology/">antipsychotic </a>agents exhibit pharmacologic action include all<br />
of the following EXCEPT:<br />
1. central nervous system<br />
2. autonomic nervous system<br />
3. cardiovascular<br />
4. endocrine system<br />
5. pulmonary</p>
<p>Item Number: 10645 correct answer: 5 category: Psychotropics<br />
9. Pharmacologic effects of cyclic antidepressants include all of the following<br />
EXCEPT:<br />
1. sedation<br />
2. flattened or inverted T waves on EKG<br />
3. urinary retention and mydriasis<br />
4. mood elevation<br />
5. raise the seizure threshold</p>
<p>Item Number: 10486 correct answer: 4 category: Psychotropics<br />
10. Uses for <a href="http://pharmacologycorner.com/powerpoints-reviewing-antipsychotics-neuroleptics-pharmacology/">antipsychotics </a>include all of the following EXCEPT:<br />
1. Gilles de la Tourette syndrome<br />
2. hiccups<br />
3. schizophrenia<br />
4. Parkinson&#8217;s disease<br />
5. manic phase of manic depression</p>
<p>Item Number: 5262 correct answer: 5 category: Psychotropics<br />
11. The pharmacological agent which is useful as an antiemetic is:<br />
1. tetracycline<br />
2. naloxone<br />
3. caffeine<br />
4. epinephrine<br />
5. chlorpromazine</p>
<p>Item Number: 10663 correct answer: 4 category: Psychotropics<br />
12. All of the following are monoamine oxidase inhibitors EXCEPT:<br />
1. phenelzine<br />
2. isocarboxazid<br />
3. tranylcypromine<br />
4. maprotiline<br />
5. All of the above</p>
<p>Item Number: 10666 correct answer: 2 category: Psychotropics<br />
13. The pharmacologic action of monoamine oxidase inhibitors is:<br />
1. block the reuptake of monoamine neurotransmitter into the presynaptic cleft<br />
2. blocks the metabolism of monoamine neurotransmitters<br />
3. decreases 5HT and NE monoamines<br />
4. enhances REM sleep<br />
5. selective MAO-B inhibitors may be useful in psychosis</p>
<p>Item Number: 10687 correct answer: 5 category: Psychotropics<br />
14. Effects of benzodiazepines include all of the following EXCEPT:<br />
1. paradoxical stimulation<br />
2. tolerance<br />
3. dependence and withdrawal<br />
4. respiratory depression in patients with obstructive lung disease<br />
5. lower seizure threshold</p>
<p>Item Number: 10681 correct answer: 1 category: Psychotropics<br />
15. Pharmacologic effects of lorazepam include:<br />
A. sedation/hypnosis<br />
B. anterograde amnesia<br />
C. increased seizure threshold<br />
D. inhibition of prolactin secretion<br />
1. A,B,C<br />
2. A,C<br />
3. B,D<br />
4. D only<br />
5. All of the above</p>
<p>Item Number: 10682 correct answer: 4 category: Psychotropics<br />
16. The elimination of all of the following benzodiazepines are influenced by<br />
liver disease or advanced aging EXCEPT:<br />
1. alprazolam<br />
2. midazolam<br />
3. chlordiazepoxide<br />
4. lorazepam<br />
5. diazepam</p>
<p>Item Number: 10648 correct answer: 4 category: Psychotropics<br />
17. The appropriately matched <a href="http://pharmacologycorner.com/differences-between-tricyclic-antidepressants-and-selective-serotonin-norepinephrine-reuptake-inhibitors-mechanism-of-action/">tricyclic antidepressant</a> and metabolite is:<br />
1. amitriptyline &#8211; desipramine<br />
2. imipramine &#8211; nortriptyline<br />
3. imipramine &#8211; trimipramine<br />
4. imipramine &#8211; desipramine<br />
5. fluoxetine &#8211; protriptyline</p>
<p>Item Number: 6702 correct answer: 2 category: Psychotropics<br />
18. A recognized <a href="http://pharmacologycorner.com/lithium-side-effects-mnemonic/">side effect of  lithium</a> carbonate is:<br />
1. hypermagnesemia<br />
2. polyuria and polydipsia<br />
3. transient fall in BUN and serum creatinine<br />
4. hypochloremia<br />
5. proximal tubular degeneration</p>
<p>Item Number: 11648 correct answer: 5 category: Psychotropics<br />
19. Endocrine effects of chlorpromazine include all of the following EXCEPT:<br />
1. decrease in adrenocorticotropins<br />
2. decrease in gonadotropins<br />
3. decrease in release of pituitary growth hormone<br />
4. increase in prolactin secretion<br />
5. decrease in thyroid hormone production</p>
<p>Item Number: 3750 correct answer: 1 category: Psychotropics<br />
20. Cholestasis is the principle derangement observed in hepatotoxicity<br />
associated with:<br />
1. phenothiazines<br />
2. monoamine oxidase inhibitors<br />
3. para-aminosalicylic acid<br />
4. carbon tetrachloride<br />
5. None of the above</p>
<p>Item Number: 11758 correct answer: 4 category: Psychotropics<br />
21. Phenelzine can result in a hypertensive crisis when coadministered with all of<br />
the following EXCEPT:<br />
1. pickled herring (tyramine)<br />
2. amphetamines<br />
3. phenylpropanolamine<br />
4. diazepam<br />
5. ephedrine</p>
<p>Item Number: 10680 correct answer: 4 category: Psychotropics<br />
22. The neurotransmitter through which benzodiazepines exert their action is:<br />
1. norepinephrine<br />
2. epinephrine<br />
3. dopamine<br />
4. gamma amino butyric acid<br />
5. <a href="http://pharmacologycorner.com/serotonin-5ht-receptors-agonists-antagonist/">serotonin</a></p>
<p>Item Number: 10612 correct answer: 1 category: Psychotropics<br />
23. The neuroleptic available as ester salts for intramuscular injection with slow<br />
absorption characteristics is:<br />
1. haloperidol<br />
2. prochlorperazine<br />
3. thioridazine<br />
4. perphenazine<br />
5. All of the above</p>
<p>Item Number: 10500 correct answer: 2 category: Psychotropics<br />
24. Anticholinergic side effects are most common with:<br />
1. haloperidol<br />
2. thioridazine<br />
3. fluphenazine<br />
4. trifluoperazine<br />
5. All of the above</p>
<p>Item Number: 11642 correct answer: 5 category: Psychotropics<br />
25. Reserpine normally has a tranquilizing effect. However, prior administration<br />
of some drugs can produce excitement in a patient taking reserpine. Classes<br />
of drugs which will produce this paradoxical effect include:<br />
1. anticholinesterases<br />
2. antihistamines<br />
3. atropine-type muscarinic blockers<br />
4. alpha-adrenergic blockers<br />
5. monoamine oxidase inhibitors</p>
<p>Item Number: 11697 correct answer: 4 category: Psychotropics<br />
26. Fluoxetine is FDA-approved to treat:<br />
1. schizophrenia<br />
2. mania<br />
3. anxiety<br />
4. depression<br />
5. obesity</p>
<p>Item Number: 11659 correct answer: 2 category: Psychotropics<br />
27. Compliance with neuroleptics medications can be increased by the<br />
administration of depot injections of:<br />
1. loxapine hydrochloride<br />
2. fluphenazine enanthate<br />
3. molindone hydrochloride<br />
4. chlorpromazine hydrochloride<br />
5. All of the above</p>
<p>Item Number: 11766 correct answer: 5 category: Psychotropics<br />
28. Drugs that reduce the <a href="http://pharmacologycorner.com/pharmacokinetics-what-is-clearance-cl-clx/">renal clearance</a> of lithium include all of the following<br />
EXCEPT:<br />
1. ibuprofen<br />
2. hydrochlorothiazide<br />
3. indomethacin<br />
4. chlorothiazide<br />
5. theophylline</p>
<p>Item Number: 11617 correct answer: 2 category: Psychotropics<br />
29. The potential central nervous system effects of haloperidol is:<br />
1. monoamine oxidase inhibition<br />
2. blockade of dopamine in the chemoreceptor trigger zone<br />
3. cholinesterase inhibition<br />
4. blockade of serotonin in the basal ganglia<br />
5. blockade of dopamine reuptake</p>
<p>Item Number: 10497 correct answer: 2 category: Psychotropics<br />
30. The correct statements regarding extrapyramidal effects of antipsychotics is:<br />
1. acute dystonic reactions occur most commonly with low potency agents<br />
2. excess dopaminergic activity is hypothesized to be a mechanism of<br />
tardive dyskinesia<br />
3. akathisia is characterized by oral facial dyskinesia<br />
4. cholinergic agents are useful in the management of neuroleptic-induced<br />
Parkinsonism<br />
5. tardive dyskinesia occurs early on in therapy and is reversible upon<br />
discontinuation of therapy</p>
<p>Item Number: 10625 correct answer: 1 category: Psychotropics<br />
31. Agents which are tricyclic or atypical cyclic antidepressants include all of<br />
the following EXCEPT:<br />
1. imipramine<br />
2. fluoxetine<br />
3. trazodone<br />
4. bupropion<br />
5. All of the above</p>
<p>Item Number: 1362 correct answer: 1 category: Psychotropics<br />
32. You treat a 40-year-old female for neurotic depression. After a few visits<br />
you prescribe amitriptyline to relieve her depression. After 4 days she calls<br />
you to say the pills are having no effect and she still feels depressed. The<br />
best course of action would be to advise her to:<br />
1. continue on the medication as prescribed, as the drug often takes up to<br />
2-6 weeks to have its antidepressant, effect<br />
2. double the dose<br />
3. stop the pills and you will order other treatment from the pharmacist<br />
4. continue on the same dose and you will call in an order for a second<br />
drug to use in combination with it<br />
5. take the pills with an alcoholic drink to increase their effect</p>
<p>Item Number: 11709 correct answer: 4 category: Psychotropics<br />
33. All of the following benzodiazepines are metabolized to active products<br />
EXCEPT:<br />
1. alprazolam<br />
2. chlordiazepoxide<br />
3. midazolam<br />
4. lorazepam<br />
5. diazepam</p>
<p>Item Number: 11705 correct answer: 4 category: Psychotropics<br />
34. The cyclic antidepressants which selectively block serotonin reuptake is:<br />
1. imipramine<br />
2. doxepin<br />
3. amoxapine<br />
4. fluoxetine<br />
5. maprotiline</p>
<p>Item Number: 10669 correct answer: 5 category: Psychotropics<br />
35. Adverse effects of monoamine oxidase inhibitors include all of the following<br />
EXCEPT:<br />
1. dry mouth, constipation, urinary retention<br />
2. hyperreflexia, fatigue, muscle twitching<br />
3. hypertensive reactions if administered with tyramine containing substances<br />
4. orthostatic hypotension<br />
5. raise seizure threshold</p>
<p>Item Number: 10499 correct answer: 5 category: Psychotropics<br />
36. Adverse effects of antipsychotic agents include all of the following EXCEPT:<br />
1. orthostatic hypotension<br />
2. mydriasis<br />
3. gynecomastia<br />
4. jaundice<br />
5. hypothyroidism</p>
<p>Item Number: 10639 correct answer: 3 category: Psychotropics<br />
37. A patient on medication develops severe hypertension after eating some cheese.<br />
The combination of substances found in the cheese and medication,<br />
respectively, which is the most likely cause of this reaction is:<br />
1. ergotamine and amphetamine<br />
2. acetylcholine and reserpine<br />
3. tyramine and phenelzine<br />
4. angiotensin and propranolol<br />
5. dopamine and phentolamine</p>
<p>Item Number: 10622 correct answer: 4 category: Psychotropics<br />
38. The correct statement which describes the dopamine theory of schizophrenia is:<br />
1. schizophrenia is due to a relative lack of the neurotransmitter dopamine<br />
2. schizophrenia is due to a relative decrease in sensitivity of<br />
postsynaptic CNS dopamine receptors<br />
3. schizophrenia is a result of a deficiency in the decarboxylase enzyme<br />
necessary for dopamine synthesis<br />
4. schizophrenia is due to a functional excess of the neurotransmitter<br />
dopamine or to a hypersensitivity of dopamine receptors or a global<br />
imbalance in dopaminergic function within the area A-10 of the brain<br />
5. All of the above</p>
<p>Item Number: 10657 correct answer: 5 category: Psychotropics<br />
39. Indications for and/or uses of cyclic antidepressants include all of the<br />
following EXCEPT:<br />
1. major depression<br />
2. eating disorders<br />
3. chronic pain<br />
4. obsessive-compulsive disorders<br />
5. epilepsy</p>
<p>Item Number: 10483 correct answer: 2 category: Psychotropics<br />
40. Correct pairs of pharmacologic action with CNS region of dopamine blockade<br />
include:<br />
A. extrapyramidal effects &#8211; basal ganglia<br />
B. increase prolactin secretion &#8211; limbic<br />
C. antiemetic &#8211; chemoreceptor trigger zone<br />
D. antipsychotic &#8211; basal ganglia<br />
1. A,B,C<br />
2. A,C<br />
3. B,D<br />
4. D only<br />
5. All of the above</p>
<p>Item Number: 11749 correct answer: 4 category: Psychotropics<br />
41. The predominant action of the demethylated biotransformation product of<br />
imipramine is inhibition of:<br />
1. serotonin synthesis<br />
2. serotonin uptake<br />
3. dopamine release<br />
4. norepinephrine uptake<br />
5. dopamine reuptake</p>
<p>Item Number: 10076 correct answer: 2 category: Psychotropics<br />
42. Lithium carbonate is used as an alternative to the major tranquilizers in<br />
the control of manic-depressive illness. After the drug is started, how many days<br />
elapse before the antimanic effect is reached?<br />
1. 1-5 days<br />
2. 7-10 days<br />
3. 11-15 days<br />
4. 16-20 days<br />
5. 21-25 days</p>
<p>Item Number: 10621 correct answer: 5 category: Psychotropics<br />
43. Drug interactions with neuroleptics include all of the following EXCEPT:<br />
1. opioids<br />
2. guanethidine<br />
3. phenobarbital<br />
4. levodopa<br />
5. furosemide</p>
<p>Item Number: 6923 correct answer: 3 category: Psychotropics<br />
44. An attempted suicide with chlorpromazine is admitted to the hospital in a<br />
semi-comatose state. Blood pressure is low. An injection of epinephrine is<br />
given to restore the cardiovascular system and the patient immediately goes<br />
into shock. Blood pressure is now unobtainable. The responsible factor is:<br />
1. chlorpromazine depresses the respiratory center<br />
2. epinephrine has a positive inotropic effect on the heart<br />
3. chlorpromazine is an alpha-adrenergic blocking agent<br />
4. chlorpromazine causes hypertension in toxic doses<br />
5. epinephrine slows the heart rate</p>
<p>Item Number: 8220 correct answer: 3 category: Psychotropics<br />
45. Compared to other major tranquilizers, thioridazine appears to produce<br />
significantly fewer instances of:<br />
1. ventricular dysrhythmias<br />
2. retinopathy<br />
3. Parkinsonism<br />
4. All of the above<br />
5. 1,3</p>
<p>Item Number: 11761 correct answer: 1 category: Psychotropics<br />
46. Adverse effects of lithium that may persist with chronic therapy include all<br />
of the following EXCEPT:<br />
1. severe nausea and vomiting<br />
2. fine tremor<br />
3. leukopenia<br />
4. polyuria<br />
5. hypothyroidism</p>
<p>Item Number: 10673 correct answer: 4 category: Psychotropics<br />
47. Adverse effects of lithium include all of the following EXCEPT:<br />
1. tremors<br />
2. polyuria<br />
3. sedation<br />
4. tardive dyskinesia<br />
5. hypothyroidism</p>
<p>Item Number: 10489 correct answer: 4 category: Psychotropics<br />
48. Extrapyramidal side effects is most common with which of the following<br />
neuroleptics?<br />
1. thioridazine<br />
2. triflupromazine<br />
3. mesoridazine<br />
4. haloperidol<br />
5. All of the above</p>
<p>Item Number: 11651 correct answer: 2 category: Psychotropics<br />
49. Cholestatic jaundice is a rare hypersensitivity reaction which reportedly<br />
occurs with:<br />
1. amitriptyline<br />
2. chlorpromazine<br />
3. lithium<br />
4. chlordiazepoxide<br />
5. alprazolam</p>
<p>Item Number: 5700 correct answer: 5 category: Psychotropics<br />
50. Overdosage of lithium carbonate prescribed for psychiatric disorders may be<br />
serious. Correct statements include:<br />
1. hemodialysis is an effective means of lithium removal and is helpful in<br />
severe overdoses<br />
2. activated charcoal binds lithium in the GI tract and prevents absorption<br />
3. symptoms include edema, tremor, polyuria, and disturbed consciousness<br />
4. All of the above<br />
5. 1,3</p>
<p>Send comments to willoughby@cctr.umkc.edu.</p>
]]></content:encoded>
			<wfw:commentRss>http://pharmacologycorner.com/mcqs-for-usmle-review-on-psychopharmacology-antipsychotics-benzodiazepines-antidepressants-and-lithium/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

<!-- Performance optimized by W3 Total Cache. Learn more: http://www.w3-edge.com/wordpress-plugins/

Minified using disk
Page Caching using disk (enhanced) (user agent is rejected)
Database Caching 4/12 queries in 0.123 seconds using disk
Content Delivery Network via cdn.pharmacologycorner.com

Served from: pharmacologycorner.com @ 2010-07-29 21:22:04 -->